Natalia Zapata‐Linares

CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I

Nerea Zabaleta, Miren Barberia, Cristina Martín-Higueras et al. · Nature Communications · 2018 · 84 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria

Rebeca Martínez-Turrillas, Ángel Martín-Mallo, Saray Rodríguez-Diaz et al. · Molecular Therapy — Methods & Clinical Development · 2022 · 22 citations · Full text

Life Sciences, Biotechnology, Molecular Biology +15

Online monitoring of hiPSC expansion and hepatic differentiation in 3D culture by dielectric spectroscopy

Inês A. Isidro, Pedro Vicente, Daniel A. M. Pais et al. · Biotechnology and Bioengineering · 2021 · 19 citations

Engineering, Bioengineering, Biomedical Engineering +16

Generation and characterization of human iPSC lines derived from a Primary Hyperoxaluria Type I patient with p.I244T mutation

Natalia Zapata‐Linares, Saray Rodríguez-Diaz, Eduardo Salido et al. · Stem Cell Research · 2015 · 18 citations · Full text

Life Sciences, Cell Biology, Genetics +17

Reversible dual inhibitor against G9a and DNMT1 improves human iPSC derivation enhancing MET and facilitating transcription factor engagement to the genome

Juan R. Rodríguez-Madoz, Edurne San José‐Eneriz, Obdulia Rabal et al. · PLoS ONE · 2017 · 16 citations · Full text

Medicine, Molecular Biology, Pharmacology +13